AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Neuromyelitis Optica

Recent research efforts aimed at curing Neuromyelitis Optica.

Last updated

Neuromyelitis Optica

Overview

Neuromyelitis optica, now usually called neuromyelitis optica spectrum disorder (NMOSD), is a rare autoimmune disease in which the immune system attacks the optic nerves, spinal cord, and sometimes other parts of the brain. In most affected people, an antibody called aquaporin-4 immunoglobulin G (AQP4-IgG) helps trigger inflammatory injury to astrocytes—support cells important for nervous-system function. NMOSD disproportionately affects women, Black Americans, and people who have other autoimmune conditions. Attacks can cause vision loss, weakness or paralysis, sensory symptoms, and bladder or bowel dysfunction; disability may accumulate because damage from attacks is often incomplete to recover. NINDS NMOSD overview NEMOS treatment recommendations

There is no established cure. Current care aims to stop acute attacks quickly with high-dose corticosteroids and plasma exchange, then prevent future attacks with long-term immune therapy. For AQP4-IgG-positive disease, maintenance options include medicines that block complement—a destructive immune pathway—deplete B cells that help produce harmful antibodies, or inhibit interleukin-6 signaling; conventional immunosuppressants and rituximab remain important options in many settings. NINDS NMOSD overview NEMOS treatment recommendations FDA Ultomiris approval letter

Scope of Recent Research (2020–present)

Research activity has expanded rapidly from relapse prevention toward the more ambitious goal of durable, treatment-free immune tolerance: a state in which the immune system no longer attacks AQP4. The dominant questions are whether pathogenic B cells and antibody-producing plasma cells can be reset safely, whether AQP4-IgG can be durably eliminated, how to predict attacks earlier, and how to repair damage already left by prior attacks. The field is not yet close to a proven curative therapy, but early immune-reset approaches—especially CAR-T cell therapy and hematopoietic stem-cell transplantation—have produced the first small clinical signals of drug-free remission. Global NMOSD trial landscape CT103A BCMA CAR-T interim results Allogeneic transplant remission report

Major Breakthroughs and Emerging Therapies

The biggest practical advance has been increasingly precise suppression of the disease mechanisms that cause attacks. In the phase 3 CHAMPION-NMOSD study, the long-acting complement inhibitor ravulizumab produced no adjudicated relapses among 58 AQP4-IgG-positive participants over 84 patient-years of treatment, compared with 20 relapses in the external placebo comparator group; however, two participants developed meningococcal infection. Long-term follow-up of the B-cell-depleting antibody inebilizumab likewise found sustained attack-rate reduction over four years, but these medicines are maintenance treatments rather than cures because treatment generally continues and immune suppression remains necessary. Ravulizumab CHAMPION-NMOSD phase 3 study Inebilizumab N-MOmentum end-of-study results

A more curative-oriented strategy is immune reconstitution: using intensive treatment to erase or deeply suppress the harmful immune repertoire and then allow a new immune system to rebuild. A 2022 systematic review of autologous hematopoietic stem-cell transplantation (AHSCT), in which a person’s own blood-forming stem cells are collected and returned after immune-depleting chemotherapy, found improved disability scores but highly variable relapse-free outcomes across only 39 severe NMOSD cases. In July 2026, long-term follow-up of two people with highly refractory AQP4-IgG-positive disease who underwent donor-derived, or allogeneic, transplantation reported 15–16 years of clinical and MRI remission without continuing immunosuppression and persistent disappearance of AQP4-IgG. These are compelling proof-of-principle observations, not evidence that transplantation is broadly safe or effective enough to be considered a routine cure. AHSCT systematic review and meta-analysis Allogeneic transplant remission report

CAR-T cell therapy is the most prominent emerging cell-based approach. CAR-T treatment engineers a patient’s T cells to recognize and destroy selected immune cells. In NMOSD, BCMA-directed CAR-T cells are designed to remove plasma cells and related antibody-producing cells, while CD19-directed products aim more broadly at B-cell populations. In an early-phase study of CT103A, a BCMA CAR-T product, 11 of 12 people with relapsed or refractory AQP4-IgG-positive NMOSD remained relapse-free at a median 5.5 months after infusion; disability and quality-of-life measures generally improved and AQP4-IgG levels trended downward. Every participant developed mild-to-moderate cytokine-release syndrome, and 58% had infections, showing both the promise and the substantial medical intensity of this strategy. CT103A BCMA CAR-T interim results

A separate preclinical route is to block the disease-causing antibody at its target rather than broadly suppress immunity. Aquaporumab is an engineered, non-destructive antibody that binds AQP4 tightly but is designed not to activate complement; in laboratory studies it competed with pathogenic AQP4-IgG and protected AQP4-expressing cells. Experimental lesion models also suggest that early complement blockade can limit lesion extension and support remyelination, the rebuilding of myelin around nerve fibers. These approaches remain preclinical and have not yet demonstrated recovery of established human disability. Affinity-matured aquaporumab study Complement inhibition and remyelination model

Clinical Trials and Experimental Approaches

The CT103A program, sponsored by Nanjing IASO Biotechnology, is an open-label early phase 1 study for relapsed or refractory antibody-associated neurological diseases, including AQP4-IgG-positive NMOSD. It uses autologous BCMA CAR-T cells after lymphodepleting cyclophosphamide and fludarabine, with NMOSD outcomes including relapse rate, MRI activity, disability, and vision measured for up to two years after infusion. The published 12-person interim NMOSD cohort provides the only substantive clinical outcome data so far, and longer follow-up remains essential. CT103A trial registry record CT103A BCMA CAR-T interim results

Other registered early studies are testing whether deeper or differently targeted B-cell depletion can produce durable remission. A phase 1 CD19 CAR-T trial in refractory NMOSD is recruiting in Zhejiang, China, with an estimated enrollment of nine people and safety as its primary aim. Tianjin Medical University General Hospital has registered a phase 1/2 anti-BAFFR CAR-T trial for up to 20 people with relapsed or refractory AQP4-IgG-positive NMOSD; it plans to track AQP4 antibody titers, B-cell levels, MRI lesions, disability, and annualized relapse rate. In the United States, UT Southwestern Medical Center registered a safety study of the CD19 CAR-T product CC-97540 for AQP4-positive NMOSD in May 2026, but it was not yet recruiting at the August 8, 2026 cutoff. CD19 CAR-T trial review BAFFR CAR-T trial registry record UT Southwestern CC-97540 trial registry record

Methodologies and Scientific Approaches

Researchers combine laboratory models with patient-derived immune measurements. Common experimental systems expose cultured astrocytes, rodent spinal cord, or optic nerve tissue to human AQP4-IgG plus complement, reproducing key features of NMOSD such as astrocyte injury, complement deposition, inflammation, and demyelination. These models are used to test complement inhibitors, AQP4-blocking antibodies, and candidate repair therapies, although they cannot fully reproduce the complexity or long-term course of human NMOSD. Experimental NMOSD optic-neuritis model Complement inhibition and remyelination model

Clinical programs increasingly use AQP4-IgG status and titer, MRI lesion activity, optical coherence tomography of the retina, visual testing, relapse rate, and disability scales to measure whether an intervention is stopping disease. Blood biomarkers are another major focus: a multicenter longitudinal study found that serum glial fibrillary acidic protein, a marker of astrocyte injury, peaked within a week of an attack, while neurofilament light, a marker of nerve-cell injury, peaked around five weeks later. Such measures may eventually help select people for immune-reset trials and distinguish suppression of inflammation from true recovery. Blood biomarkers of AQP4-positive NMOSD activity

Leading Institutions and Funding

Major academic and clinical contributors include Mayo Clinic, the University of Colorado Anschutz Medical Campus, the University of California San Francisco, Northwestern University, and collaborating NMOSD centers in Europe and Asia. Chinese centers and biotechnology groups have been particularly active in translating CAR-T concepts to NMOSD, including CT103A studies and newer CD19- and BAFFR-directed programs; Hadassah Medical Organization in Israel is also running a phase 1 BCMA CAR-T platform trial that includes a refractory AQP4-IgG-positive NMOSD cohort. CT103A BCMA CAR-T interim results HBI0101 BCMA CAR-T trial registry record

The Guthy-Jackson Charitable Foundation has played an unusually central convening and funding role in this rare disease, reporting more than $70 million invested in over 90 research studies since 2008. The foundation also reports that NIH support for NMO research has exceeded $98 million since 2008, while NINDS remains the principal U.S. federal funder of neurological-disorder research. These investments support multicenter networks, clinical cohorts, biobanking, biomarker work, and trial infrastructure needed for small, geographically dispersed patient populations. Guthy-Jackson Foundation history and investments Guthy-Jackson research funding overview NINDS NMOSD overview

Strengths, Limitations, and Challenges

The field’s core strength is unusually clear biology for AQP4-IgG-positive NMOSD: the pathogenic antibody, B-cell lineage, interleukin-6 pathway, and complement cascade provide concrete therapeutic targets. That clarity has already produced highly effective attack-prevention therapies and makes AQP4-IgG-positive disease a plausible setting for immune-reset treatments. Yet preventing a new attack is not equivalent to curing the disease, and neither standard biologics nor early CAR-T studies have established that they restore vision, spinal-cord function, or long-term immune tolerance in a broad population. NEMOS treatment recommendations Ravulizumab CHAMPION-NMOSD phase 3 study CT103A BCMA CAR-T interim results

The curative candidates also carry major risks and evidence gaps. Complement blockade increases susceptibility to meningococcal infection; CAR-T requires cell collection, manufacturing, lymphodepleting chemotherapy, specialized inpatient monitoring, and management of cytokine-release syndrome and infections; and transplantation can cause severe short- and long-term toxicity. NMOSD is rare, trial cohorts are small, and the strongest immune-reset reports have short follow-up or only one or two patients, making it impossible to know which people can safely stop treatment, whether AQP4-IgG negativity will last, or whether benefit extends to AQP4-IgG-negative NMOSD. Ravulizumab CHAMPION-NMOSD phase 3 study AHSCT systematic review and meta-analysis Allogeneic transplant remission report

Outlook and Future Directions

As of August 8, 2026, NMOSD has entered an era in which relapses can often be dramatically reduced, but a scalable cure has not been demonstrated. The most important milestones to watch are multi-year results from BCMA-, CD19-, and BAFFR-directed CAR-T studies; confirmation that people can remain relapse-free and off immunotherapy after B-cell reconstitution; controlled comparisons of immune-reset strategies with modern biologics; and therapies that combine durable immune tolerance with repair of pre-existing optic-nerve and spinal-cord damage. If these studies show sustained AQP4-IgG elimination, acceptable safety, and drug-free remission in larger cohorts, NMOSD could become one of the first antibody-mediated neurological diseases in which a functional cure is realistically testable. CT103A BCMA CAR-T interim results BAFFR CAR-T trial registry record Allogeneic transplant remission report

References

Don't see your disease? Request a report